62nd ASH Annual Meeting and Exposition: 704. Immunotherapies: Beyond T to NK

Oral and Poster Abstracts
Oral

Biological, Adult, AML, antibodies, Follicular Lymphoma, Leukemia, Diseases, iPSCs, Lymphoma (any), Therapies, Combinations, MDS, Non-Hodgkin Lymphoma, B-Cell Lymphoma, DLBCL, Immune Disorders, immune cells, immunotherapy, Cell Lineage, Lymphoid Malignancies, Study Population, Myeloid Malignancies, NK cells, Clinically relevant, transplantation

Moderators:

Premal Lulla, MBBS, Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, Houston Methodist Hospital and Melinda Ann Biernacki, MD,

Disclosures:

No relevant conflicts of interest to declare.

7:30 AM

Results of a Phase 1 Trial of Gda-201, Nicotinamide-Expanded Allogeneic Natural Killer (NK) Cells in Patients with Refractory Non-Hodgkin Lymphoma (NHL) and Multiple Myeloma

Veronika Bachanova, MD, PhD¹, Joseph Maakaron, MD¹^*, David H. McKenna, MD², Qing Cao, MS³^*, Todd E. DeFor, MS⁴^*, Fiona He, MD⁵, Murali Janakiram, MD⁶, Rose Wangen¹^*, Zuzan Cayci, MD⁷^*, Bartosz Grzywacz, MD², Ronit Simantov, MD⁸, Tracey Lodie, PhD⁹^* and Jeffrey S. Miller, MD¹

¹Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN
²Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN
³University of Minnesota, Minneapolis, MN
⁴Biostatistics Core, Masonic Cancer Center, University of Minnesota, Minneapolis, MN
⁵Unniversity of Minnesota, Minneapolis, MN
⁶Division of Hematology, Oncology and Transplantation, University of Minnesota, Rochester, MN
⁷Department of Radiology, University of Minnesota, Minneapolis, MN
⁸Gamida Cell, New Haven, CT
⁹Gamida Cell, Boston, MA

7:45 AM

Phase 1 Trial of Prophylactic Donor-Derived IL-2 Activated NK Cell Infusion after Allogeneic Hematopoietic Stem Cell Transplantation from a Matched Sibling Donor

Raynier Devillier^1,2,3^*, Boris Calmels, Pharm.D.⁴^*, Sophie Guia⁵^*, Cyril Fauriat⁶^*, Sabine Furst¹^*, Samia Harbi¹^*, Angela Granata, MD¹^*, Sophie Ugolini⁷^*, Christian Chabannon, MD, PhD^1,2,8, Daniel Olive, MD, PhD⁹^*, Eric Vivier¹⁰^* and Didier Blaise, MD¹

¹Institut Paoli Calmettes, Marseille, France
²CRCM / INSERM U1068, Marseille, France
³Aix Marseille University, Medicine Faculty, Marseille, France
⁴Institut Paoli Calmettes, Cell Therapy Facility, Paoli Calmettes Institut, Marseille, France
⁵CIML, Marseille, FRA
⁶Immunity and Cancer, Cancer Research Center of Marseille (CRCM), INSERM 1068, Marseille, France
⁷CIML, Marseille Cedex 09, FRA
⁸Cell Therapy Facility, Paoli Calmettes Institute, Marseille, France
⁹INSERM UMR 1068 Institut Paoli Calmettes, Marseille, France
¹⁰Centre D'Immunologie De Marseilla-Luminy (CIML), Marseille, FRA

8:00 AM

GTB-3550 TriKE™ for the Treatment of High-Risk Myelodysplastic Syndromes (MDS) and Refractory/Relapsed Acute Myeloid Leukemia (AML) Safely Drives Natural Killer (NK) Cell Proliferation At Initial Dose Cohorts

Erica D. Warlick, MD¹, Daniel J. Weisdorf, MD², Daniel A. Vallera, PhD³^*, Rose Wangen¹^*, Dixie Lewis, RN, BA⁴^*, JoAnn Knox⁴^*, Martin Schroeder⁵^*, Martin Felices, PhD¹^* and Jeffrey S. Miller, MD²

¹Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN
²Department of Medicine, Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, MN
³Department of Therapeutic Radiology-Radiation Oncology, University of Minnesota, Minneapolis, MN
⁴Masonic Cancer Center, University of Minnesota, Minneapolis, MN
⁵GT Biopharma, Beverly Hills, CA

8:15 AM

Cytokine-Induced Memory-like NK Cells Exhibit Massive Expansion and Long-Term Persistence after Infusion Post-Haploidentical Stem Cell Transplantation: A Report of the First Three Cases in a Phase I Trial

Roman M Shapiro, MD¹, Sarah Nikiforow, MD, PhD², Benedetta Rambaldi, MD², Juliana Vergara³^*, Heather Daley⁴^*, Haesook T. Kim, PhD⁵, Corey Cutler, MD, MPH, FRCPC ⁶, Vincent T. Ho, MD⁴^*, John Koreth, MBBS, DPhil¹, Mahasweta Gooptu, MD², Joseph H. Antin, MD², Jennifer Brock¹^*, Catherine J. Wu, MD⁴, Robert J. Soiffer, MD², Jerome Ritz, MD² and Rizwan Romee, MD⁷

¹Dana-Farber Cancer Institute, Boston, MA
²Dana-Farber Cancer Institute, Department of Hematologic Malignancies and Harvard Medical School, Boston, MA
³Harvard Medical School, Boston, MA
⁴Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
⁵Department of Data Science, Dana-Farber Cancer Institute, Boston, MA
⁶Division of Stem Cell Transplantation and Cellular Therapy, Dana-Farber Cancer Inst., Boston, MA
⁷Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA

8:30 AM

Engineered iPSC-Derived NK Cells Expressing Recombinant CD64 for Enhanced ADCC

Kate Dixon, PhD¹^*, Robert Hullsiek²^*, Kristin Snyder²^*, Zachary Davis, PhD, BS³^*, Melissa Khaw³^*, Tom Lee, PhD⁴^*, Hui-Yi Chu, PhD⁵^*, Ramzey Abujarour, PhD⁴^*, Jason Dinella, PhD⁵^*, Paul Rogers, PhD⁵^*, Ryan Bjordahl, PhD⁵^*, Jeffrey S. Miller, MD^6,7, Bahram Valamehr, PhD⁴, Jianming Wu, PhD²^* and Bruce Walcheck, PhD²^*

¹Veterinary and Biomedical Sciences, University of Minnesota, St Paul, MN
²Veterinary and Biomedical Sciences, University of Minnesota, Saint Paul, MN
³Masonic Cancer Center, University of Minnesota, Minneapolis, MN
⁴Fate Therapeutics, Inc., San Diego, CA
⁵Fate Therapeutics Inc., San Diego, CA
⁶Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN
⁷Department of Medicine, Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, MN

8:45 AM

Haploidentical Mbil-21 Ex Vivo Expanded NK Cells (FC21-NK) for Patients with Multiple Relapsed and Refractory Acute Myeloid Leukemia

Stefan O. Ciurea, MD¹, Jolie Schafer²^*, Piyanuch Kongtim, MD¹^*, Julianne Chen³^*, Doris Soebbing⁴^*, Kai Cao, MS, MD⁵, Samer A. Srour, MD, MS⁶, Elizabeth J. Shpall, MD¹, Marina Konopleva, MD, PhD⁷, Dean Anthony Lee, MD, PhD⁸ and Richard E. Champlin, MD¹

¹Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
²Kiadis Pharma, Amsterdam, NLD
³The University of Texas MD Anderson Cancer Center, Houston, TX
⁴Department of Stem Cell Transplantation and Cellular Therapy, The University of Taxas MD Anderson Cancer Center, Houston
⁵Department of Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
⁶Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
⁷University of Texas, MD Anderson Cancer Center, Houston, TX
⁸Center for Childhood Cancer and Blood Diseases, Abigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, OH

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

704.O2.6 704. Immunotherapies: Beyond T to NK